{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:08:28Z","timestamp":1792278508680,"version":"4.4.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Tolvaptan, a vasopressin V2 receptor antagonist, is the only proven renoprotective therapy for patients with autosomal dominant polycystic kidney disease (ADPKD), but aquaretic side effects limit its tolerability. Currently, no patient-reported outcome measures (PROMs) specifically assess the impact of tolvaptan on health-related quality of life (HRQoL) in ADPKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed the tolvaptan impact of polyuria scale (TIPS) questionnaire to evaluate tolvaptan-related treatment burden, with higher scores indicating greater burden. The TIPS, alongside the ADPKD-Urinary Impact Scale (ADPKD-UIS) and Short-Form 12 (SF-12) questionnaires, was administered to 152 participants: 47 healthy controls and repeatedly in 105 patients with ADPKD, including those that were untreated (n =\u00a048), on a stable tolvaptan dose (n =\u00a033), or undergoing tolvaptan dose titration (n =\u00a024). All participants also completed standardized 24-h urine collections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Untreated patients with ADPKD reported a lower HRQoL than healthy controls. Tolvaptan-treated patients had significantly higher 24-h urine volumes (5139\u00a0\u00b1\u00a0193 vs. 2474 \u00b1 180 ml, P &amp;lt;\u00a0.001), with elevated TIPS total (48.0\u00a0\u00b1\u00a03.8 vs. 37.3\u00a0\u00b1\u00a03.4, p =\u00a00.04) and ADPKD-UIS total scores (19.2\u00a0\u00b1\u00a01.0 vs. 15.6\u00a0\u00b1\u00a00.9, P =\u00a0.01) compared to untreated patients, reflecting treatment burden. Twenty-four hour urine volume correlated with TIPS total [r = 0.56 (95% CI: 0.38, 0.78, P &amp;lt;\u00a0.001)] and ADPKD-UIS total scores [r = 0.71 (95% CI: 0.58, 0.83, P &amp;lt;\u00a0.001)], but not with SF-12 scores. TIPS scores were stable over time in treated- and untreated ADPKD patients. During tolvaptan titration, the greatest changes in 24-h urine volume and HRQoL occurred at the initial dose (45\/15 mg), with significant treatment burden across HRQoL domains. Among patients who discontinued tolvaptan during titration due to aquaretic side effects, unlike the ADPKD-UIS, TIPS scores were higher compared to those who continued treatment, suggesting better differentiation by the TIPS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tolvaptan treatment significantly impacts HRQoL in ADPKD. The TIPS questionnaire effectively captures the physical, mental, and social burden of tolvaptan-induced polyuria, and provides a reliable PROM for clinical care and research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfag102","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T11:32:13Z","timestamp":1778412733000},"source":"Crossref","is-referenced-by-count":1,"title":["Measuring the impact of tolvaptan-induced polyuria on quality of life in patients with autosomal dominant polycystic kidney disease"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3649-6948","authenticated-orcid":false,"given":"Thomas","family":"Bais","sequence":"first","affiliation":[{"name":"University Medical Center Groningen, University of Groningen Division of Nephrology, Department of Internal Medicine, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-9727","authenticated-orcid":false,"given":"Paul","family":"Geertsema","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen Division of Nephrology, Department of Internal Medicine, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hanke","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen Division of Nephrology, Department of Internal Medicine, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6520-6830","authenticated-orcid":false,"given":"Anna M","family":"Posthumus","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen Division of Nephrology, Department of Internal Medicine, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3356-6791","authenticated-orcid":false,"given":"Stephan J L","family":"Bakker","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen Division of Nephrology, Department of Internal Medicine, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7875-1793","authenticated-orcid":false,"given":"Esther","family":"Meijer","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen Division of Nephrology, Department of Internal Medicine, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3223-0906","authenticated-orcid":false,"given":"Ron T","family":"Gansevoort","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen Division of Nephrology, Department of Internal Medicine, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2026061510533040800_bib1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ndt\/gfab312","article-title":"An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on inherited kidney disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International","volume":"37","author":"M\u00fcller","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026061510533040800_bib2","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","article-title":"Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3:4","volume":"2","author":"Devuyst","year":"2017","journal-title":"Kidney Int Rep"},{"key":"2026061510533040800_bib3","doi-asserted-by":"publisher","first-page":"22257","DOI":"10.1038\/s41598-023-48638-9","article-title":"Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort","volume":"13","author":"Calvaruso","year":"2023","journal-title":"Sci Rep"},{"key":"2026061510533040800_bib4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/ndt\/gfad218","article-title":"Effects of salt and protein intake on polyuria in V2RA-treated ADPKD patients","volume":"39","author":"Geertsema","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026061510533040800_bib5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2215\/CJN.11260821","article-title":"Effects of hydrochlorothiazide and metformin on aquaresis and nephroprotection by a vasopressin V2 receptor antagonist in ADPKD: a randomized crossover trial","volume":"17","author":"Kramers","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026061510533040800_bib6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13063-024-07952-x","article-title":"HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial","volume":"25","author":"Bais","year":"2024","journal-title":"Trials"},{"key":"2026061510533040800_bib7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care"},{"key":"2026061510533040800_bib8","first-page":"225","article-title":"Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument","volume-title":"Am J Kidney Dis","author":"Oberdhan","year":"2018"},{"key":"2026061510533040800_bib9","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","article-title":"Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2\u2014assessing respondent understanding","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"2026061510533040800_bib10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","article-title":"Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2014eliciting concepts for a new PRO instrument","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"2026061510533040800_bib11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2026061510533040800_bib12","article-title":"A practical guide to sensitivity analysis for causal effects in the presence of non-ignorable loss to follow-up","author":"Khalifa"},{"key":"2026061510533040800_bib13","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v045.i03","article-title":"mice\u202f: multivariate Imputation by Chained Equations in R","volume":"45:1\u201367","author":"Buuren","year":"2011","journal-title":"J Stat Soft"},{"key":"2026061510533040800_bib14","doi-asserted-by":"publisher","article-title":"rmcorr: repeated measures correlation. CRAN: contributed Packages","author":"Bakdash","DOI":"10.32614\/CRAN.package.rmcorr"},{"key":"2026061510533040800_bib15","doi-asserted-by":"publisher","first-page":"906","DOI":"10.2215\/CJN.11311111","article-title":"Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment","volume":"7","author":"Zittema","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026061510533040800_bib16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/ki.1989.38","article-title":"The clinical utility of renal concentrating capacity in polycystic kidney disease","volume":"35","author":"Gabow","year":"1989","journal-title":"Kidney Int"},{"key":"2026061510533040800_bib17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrneph.2012.139","article-title":"Polycystic kidney disease: an early urea-selective urine-concentrating defect in ADPKD","volume":"8","author":"Bankir","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"2026061510533040800_bib18","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1007\/s10557-011-6299-3","article-title":"Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers","volume":"25","author":"Kim","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026061510533040800_bib19","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/j.ekir.2023.05.011","article-title":"Interaction between determinants governing urine volume in patients with ADPKD on tolvaptan and its impact on quality of life","volume":"8","author":"Todorova","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026061510533040800_bib20","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","article-title":"Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2\u2014assessing respondent understanding","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag102\/68269225\/gfag102.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag102\/68269225\/gfag102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:53:40Z","timestamp":1781535220000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article\/doi\/10.1093\/ndt\/gfag102\/8676049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":20,"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag102","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"gfag102"}}